US$150 million invested to expand US pharmaceutical distribution network

(Copyright: DHL Supply Chain).

Logistics company, DHL Supply Chain (which is part of the Deutsche Post DHL Group) is expanding its pharmaceutical and medical device distribution network by 40 percent this year with a total investment of $150 million.

This is to achieve an ultimate goal of bringing healthcare products closer to trade partners and patients. The company has plans for nine new sites by the end of 2019 and this investment includes costs to invest in new buildings and technology, as well as the fit-out and start-up of new or expanded operations.

“This expansion allows DHL Supply Chain to continue to deepen the connections between our customers and the patients they serve,” said Scott Cubbler, President of Life Sciences and Healthcare at DHL Supply Chain. “This most recent expansion also helps us leverage differentiated routes to market, driving even greater efficiency and productivity across the supply chain for our customers.

“With this expansion, DHL Supply Chain will have a total of 30 sites designed to support pharmaceutical, biotech, and medical device companies.”

These distribution sites, strategically located within the United States, are fully licensed with a temperature controlled space that supports pharmaceutical storage requirements. The sites also allow for packaging and managed transportation for integrated solutions.